{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:24:43Z","timestamp":1793701483936,"version":"4.5.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2T32HL083808-06"],"award-info":[{"award-number":["2T32HL083808-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.rdc.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T18:41:01Z","timestamp":1445884861000},"page":"157-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":408,"title":["Infection Risk and Safety of Corticosteroid Use"],"prefix":"10.1016","volume":"42","author":[{"given":"Jameel","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon A.","family":"Novosad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.rdc.2015.08.004_bib1","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/art.21298","article-title":"Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial","volume":"52","author":"Svensson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.004_bib2","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/art.21421","article-title":"Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial","volume":"52","author":"Wassenberg","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.004_bib3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis and management","volume":"112","author":"Lukert","year":"1990","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.004_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature","volume":"20","author":"Kersey","year":"2006","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.004_bib8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.autrev.2010.06.007","article-title":"Steroid induced osteonecrosis: an analysis of steroid dosing risk","volume":"9","author":"Powell","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12020-011-9580-0","article-title":"Glucocorticoid-induced osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrine"},{"issue":"1\u20132","key":"10.1016\/j.rdc.2015.08.004_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-0173(96)00012-4","article-title":"The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions","volume":"23","author":"McEwen","year":"1997","journal-title":"Brain Res Brain Res Rev"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.004_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.7326\/0003-4819-119-12-199312150-00007","article-title":"Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib13","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.4049\/jimmunol.173.6.3816","article-title":"Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death","volume":"173","author":"Purton","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib14","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.004_bib15","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.004_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/anr.1780320422","article-title":"Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders","volume":"32","author":"Goldenberg","year":"1989","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01533366","article-title":"T\u00a0helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity","volume":"14","author":"Bermas","year":"1994","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.1995.tb02277.x","article-title":"Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE)","volume":"101","author":"Marquart","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.004_bib19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/acr.22575","article-title":"Burden of serious infections in adults with systemic lupus erythematosus. A national population-based study, 1996-2011","volume":"67","author":"Tektonidou","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.004_bib20","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.004_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2003.014050","article-title":"Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial","volume":"63","author":"Capell","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/ard.2007.076299","article-title":"Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis","volume":"67","author":"Choy","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.004_bib23","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1002\/art.23055","article-title":"Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone","volume":"56","author":"Durez","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.004_bib24","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/art.20664","article-title":"Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis","volume":"50","author":"Gerlag","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/ard.2003.008573","article-title":"A\u00a0randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis","volume":"63","author":"Kirwan","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.004_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00296-002-0278-8","article-title":"Ileum-targeted steroid therapy in rheumatoid arthritis: double-blind, placebo-controlled trial of controlled-release budesonide","volume":"23","author":"Sheldon","year":"2003","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2011-201067","article-title":"Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)","volume":"72","author":"Buttgereit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/j.rdc.2015.08.004_bib30","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.004_bib31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib33","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.004_bib35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.004_bib36","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/ard.2006.057265","article-title":"Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis","volume":"66","author":"Franklin","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.004_bib39","doi-asserted-by":"crossref","first-page":"215692","DOI":"10.5402\/2012\/215692","article-title":"The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai","volume":"2012","author":"Xie","year":"2012","journal-title":"ISRN Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/rheumatology\/kes413","article-title":"Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the dutch rheumatoid arthritis monitoring (DREAM) registry","volume":"52","author":"van Dartel","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.004_bib41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201205-0825OC","article-title":"Environment or host?: a case-control study of risk factors for mycobacterium avium complex lung disease","volume":"186","author":"Dirac","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3201\/eid1702.101020","article-title":"Risk factors for cryptococcus gattii infection, british columbia, canada","volume":"17","author":"MacDougall","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib43","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1186\/cc3488","article-title":"Isolation of aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome","volume":"9","author":"Garnacho-Montero","year":"2005","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1213\/ane.0b013e3181607262","article-title":"Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome","volume":"106","author":"Dimopoulos","year":"2008","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00296-008-0721-6","article-title":"Risk factors of pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus","volume":"29","author":"Lertnawapan","year":"2009","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/acr.20435","article-title":"Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series","volume":"63","author":"Kermani","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.004_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","article-title":"Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid","volume":"21","author":"Chew","year":"2015","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/rheumatology\/keq314","article-title":"Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome","volume":"50","author":"Mekinian","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/03009742.2011.630328","article-title":"High prevalence of pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy","volume":"41","author":"Fritzsche","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib51","first-page":"615","article-title":"Increased risk of pneumocystis carinii pneumonia in patients with wegener's granulomatosis","volume":"11","author":"Jarrousse","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Invest"},{"issue":"3 Pt 1","key":"10.1016\/j.rdc.2015.08.004_bib53","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener's granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.004_bib54","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A\u00a0prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.004_bib55","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s10067-013-2293-4","article-title":"Should pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?","volume":"32","author":"Besada","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.004_bib56","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/ard.54.12.991","article-title":"Factors associated with pneumocystis carinii pneumonia in wegener's granulomatosis","volume":"54","author":"Godeau","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib57","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.004_bib58","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.004_bib59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.004_bib60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2015.08.004_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease modifying anti-rheumatic drugs","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2015.08.004_bib62","article-title":"Psoriatic arthritis treatment and the risk of herpes zoster","author":"Zisman","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.004_bib63","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archdermatol.2009.152","article-title":"Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm","volume":"145","author":"Fardet","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2015.08.004_bib64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2334-13-78","article-title":"Severe strongyloidiasis: a systematic review of case reports","volume":"13","author":"Buonfrate","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.004_bib65","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/030097402760375205","article-title":"Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in hong kong","volume":"31","author":"Tam","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.004_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1741-7015-11-97","article-title":"Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies","volume":"11","author":"Ramagopalan","year":"2013","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib70","first-page":"9","article-title":"Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population","volume":"16","author":"Kim","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in quebec, canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib72","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib73","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib74","first-page":"292","article-title":"Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the united states","volume":"107","author":"Davis","year":"2014","journal-title":"Southampt Med J"},{"key":"10.1016\/j.rdc.2015.08.004_bib75","unstructured":"Shingles (Herpes Zoster). Centers for Disease Control and Prevention. 2014. Available at: http:\/\/www.cdc.gov\/vaccines\/vpd-vac\/shingles\/hcp-vaccination.htm. Accessed June 12, 2015."},{"issue":"22","key":"10.1016\/j.rdc.2015.08.004_bib76","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A\u00a0vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2015.08.004_bib77","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/annrheumdis-2014-eular.5983","article-title":"Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination","volume":"73","author":"Curtis","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.004_bib78","unstructured":"ZOSTAVAX Zoster Vaccine Live Product Information. Available at: MerckVaccines.com. Accessed June 12, 2015."},{"issue":"5","key":"10.1016\/j.rdc.2015.08.004_bib79","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2015.08.004_bib80","unstructured":"Contraindications and Precautions to Commonly Used Vaccines in Adults. Centers for Disease Control and Prevention. 2015. Available at: http:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult-contraindications.html. Accessed June 12, 2015."},{"issue":"RR-6","key":"10.1016\/j.rdc.2015.08.004_bib81","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American thoracic society","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.004_bib82","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semarthrit.2012.07.001","article-title":"Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in korean patients with rheumatic diseases","volume":"42","author":"Kim","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.004_bib83","first-page":"291031","article-title":"Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test","volume":"2014","author":"Arenas Miras Mdel","year":"2014","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.004_bib84","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.004_bib85","first-page":"1271","article-title":"Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.004_bib86","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22454","article-title":"Indeterminate QuantiFERON-TB gold in-tube results in patients with chronic inflammatory diseases on immunosuppressive therapy","volume":"67","author":"Calabrese","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.004_bib87","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1183\/09031936.00107608","article-title":"QuantiFERON-TB gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases","volume":"33","author":"Bartalesi","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2015.08.004_bib88","unstructured":"Recommended Adult Immunization Schedule\u2013United States - 2015. Centers for Disease Control and Prevention. Available at: http:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/adult.html. Accessed June 12, 2015."}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1500068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1500068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:14:22Z","timestamp":1760181262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X1500068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889857X1500068X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection Risk and Safety of Corticosteroid Use","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}